Low-Dose Alemtuzumab-Based Induction in Kidney Transplantation: A Retrospective Comparison of Maintenance Immunosuppression, Long-Term Graft Outcomes, and Induction Costs

Abstract

Background: Alemtuzumab is a lymphocyte-depleting monoclonal antibody used for induction immunosuppression in kidney transplantation. Its prolonged immunological effects may permit minimization of maintenance immunosuppression. This study compared long-term outcomes, maintenance immunosuppression requirements, complications, and reported induction costs between recipients receiving low-dose alemtuzumab and those receiving conventional induction.

Methods: This retrospective comparative study included kidney transplant recipients who underwent transplantation between 2006 and 2014. Recipients receiving 10 mg subcutaneous alemtuzumab before transplantation were compared with recipients receiving antithymocyte globulin (ATG) or basiliximab. Follow-up extended through 2019. Outcomes included acute rejection, graft loss, death with a functioning graft, lymphocytopenia, maintenance immunosuppression, metabolic complications, malignancy, and induction costs. The available abstract provided aggregate outcome counts; detailed statistical methods and baseline characteristics were not available for this manuscript preparation.

Results: The study included 177 recipients: 75 in the alemtuzumab group and 102 in the conventional-induction group. Acute rejection occurred in 2/75 (2.7%) and 8/102 (7.8%), respectively. Triple-drug maintenance immunosuppression was reported in 13/75 (17.3%) recipients receiving alemtuzumab and 94/102 (92.2%) receiving conventional induction. Dyslipidemia was reported in 12/75 (16.0%) and 56/102 (54.9%), respectively, while hypertension requiring more than two antihypertensive medications was reported in 12/75 (16.0%) and 82/102 (80.4%). Graft failure beyond five years was reported in 3/75 (4.0%) and 22/102 (21.6%). Induction costs were reported as below US$500 per patient in the alemtuzumab group and above US$1,000 in the conventional-induction group. The abstract reported significant differences in several outcomes but did not provide complete statistical output.

Conclusion: In this retrospective cohort, low-dose alemtuzumab induction was associated with lower use of triple-drug maintenance immunosuppression, lower reported frequencies of selected metabolic complications, fewer reported graft failures beyond five years, and lower induction costs. These findings are hypothesis-generating. Complete statistical verification, adjustment for confounding, and a formal economic analysis are required before concluding that alemtuzumab improves long-term outcomes or is cost-effective.